SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important for the immune response.
Investigated for use/treatment in multiple sclerosis and rheumatoid arthritis.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.